目的:探讨低表达miR-210-3p对大鼠垂体瘤GH3和MMQ细胞株的增殖与迁移的作用。方法:将培养好的大鼠垂体瘤MMQ与GH3细胞株随机分为低表达miR-210-3p组和阴性对照组,分别转染miR-210-3p inhibitor和miR-210-3p NC,荧光定量PCR检测实验组与对照组的miR-210-3p的表达;转染后24 h、48 h、72 h分别进行CCK8检测增殖能力;用Transwell来检测大鼠垂体瘤细胞的迁移能力;用Western- boltting技术分别检测低表达miR-210-3p组和阴性对照组的FGFRL-1的蛋白表达;用双荧光素酶实验验证miR-210-3p的靶基因。结果:转染低表达病毒后MMQ与GH3垂体瘤细胞株的细胞增殖能力下降较阴性对照组比较差异,P < 0.05,有统计学意义;低表达miR-210-3p组MMQ与GH3垂体瘤细胞系与阴性对照组相比细胞迁移能力下降,P < 0.05,有统计学意义;转染低表达病毒组的细胞株与对照组相比,靶基因蛋白表达有差异,P < 0.05;miR-210-3p可与FGFRL-1 mRNA的3’-UTR结合,FGFRL-1为miR-210-3p的靶基因。结论:miR-210-3p低表达抑制大鼠垂体瘤细胞的增殖与迁移。
Objective: To investigate the role of miR-210-3p in regulating the proliferation and migration of GH3 and MMQ cell lines. Methods: The cultured rat pituitary adenoma MMQ and GH3 cell lines were randomly divided into the low-expression miR-210-3p group and the negative control group. The expression of miR-210-3p was transfected with miR-210-3p inhibitor and miR-210-3p NC, respectively. After transfection, proliferation capacity of CCK8 was detected at 24 h, 48 h and 72 h, respectively. Transwell was used to detect the migration ability of pituitary tumor cells in rats. The protein expression of fgfrl-1 in the low miR-210-3p group and the negative control group was detected by western-boltting technique. The target genes of miR-210-3p were verified by double luciferase assay. Results: After transfection with the low expression virus, the decreased cell proliferation of the pituitary adenoma cell lines MMQ and GH3 was significantly lower than that of the negative control group (P < 0.05). Compared with the negative control group, MMQ and GH3 pituitary adenoma cell lines in the low-expression miR-210-3p group showed decreased cell migration, P < 0.05, which was statistically significant. Compared with the control group, the expression of target gene protein was different in the transfected low-expression virus group (P < 0.05). miR-210-3p can bind to 3'-utr of FGFRL-1 mRNA, and FGFRL-1 is the target gene of miR-210-3p. Conclusion: The low expression of miR-210-3p inhibited the proliferation and migration of MMQ and cells.
miR-210-3p,FGFRL-1,大鼠垂体瘤细胞株,增殖,迁移, miR-210-3p FGFRL-1 Rat Pituitary Adenoma Cell Line Proferation Migration低表达miR-210-3p调控大鼠垂体瘤GH3与MMQ细胞株增殖与迁移
王成浩,谭维康,蒋亚楠,王建鹏,姚维成. 低表达miR-210-3p调控大鼠垂体瘤GH3与MMQ细胞株增殖与迁移The Low Expression of miR-210-3p Regulates the Proliferation and Migration of GH3 and MMQ Cell Lines in Rat Pituitary Adenoma[J]. 临床医学进展, 2020, 10(07): 1260-1268. https://doi.org/10.12677/ACM.2020.107192
参考文献References王忠诚. 王忠诚神经外科学[M]. 武汉: 湖北科学技术出版社, 2005: 620.Rey, J.A., Bello, M.J., de Campos, J.M., et al. (1986) A Case of Pituitary Adenoma with 58 Chromosomes. Cancer Genetics and Cytogenetics, 23, 171-174. <br>https://doi.org/10.1016/0165-4608(86)90415-2Roelfsema, F., Biermasz, N.R. and Pereira, A.M. (2012) Clinical Factors Involved in the Recurrence of Pituitary Adenomas after Surgical Remission: A Structured Review and Meta-Analysis. Pituitary, 15, 71-83.
<br>https://doi.org/10.1007/s11102-011-0347-7Day, P.F., Loto, M.G., Glerean, M., et al. (2016) Incidence and Prevalence of Clinically Relevant Pituitary Adenomas: Retrospective Cohort Study in a Health Management Organization in Buenos Aires, Argentina.Yang, W. (2011) Progress on Hypoxic Regulatory Factor miR-210. Chinese Journal of Pathophysiology, 27, 813.杨巍. 乏氧调控因子miR-210的研究进展[J]. 中国病理生理杂志, 2011, 27(4): 813.Giannakakis, A., Sandaltzopoulos, R., Greshock, J., et al. (2007) miR-210 Links Hypoxia with Cell Cycle Regulation and Is Deleted in Human Epithelial Ovarian Cancer. Cancer Biology & Therapy, 7, 255.
<br>https://doi.org/10.4161/cbt.7.2.5297Fasanaro, P., Alesandra, Y., Stefano, V., et al. (2008) MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3. Journal of Biological Chemistry, 283, 15878- 15883. <br>https://doi.org/10.1074/jbc.M800731200Gee, H.E., Camps, C., Buffa, F.M., Patiar, S., Winter, S.C., Betts, G., Homer, J., Corbridge, R., Cox, G., West, C.M., Ragoussis, J. and Harris, A.L. (2010) hsa-mir-210 Is a Marker of Tumor Hypoxia and a Prognostic Factor in Head and Neck Cancer. Cancer, 116, 2148-2158. <br>https://doi.org/10.1002/cncr.25009Ho, A.S., Huang, X., Cao, H., Christman-Skieller, C., Bennewith, K., Le, Q.T. and Koong, A.C. (2010) Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Translational Oncology, 3, 109-113.
<br>https://doi.org/10.1593/tlo.09256di Martino, E., Taylor, C.F., Roulson, J.A. and Knowles, M.A. (2013) An Integrated Genomic, Transcriptional and Protein Investigation of FGFRL1 as a Putative 4p16.3 Deletion Target in Bladder Cancer. Genes Chromosomes Cancer, 52, 860-871. <br>https://doi.org/10.1002/gcc.22082Schild, C. and Trueb, B. (2005) Aberrant Expression of FGFRL1, a Novel FGF Receptor, in Ovarian Tumors. International Journal of Molecular Medicine, 16, 1169-1173. <br>https://doi.org/10.3892/ijmm.16.6.1169徐川, 张怀壁, 康继辉, 等. miRNA在PRL型垂体瘤患者血清中的表达[J]. 世界中西医结合杂志, 2015(4): 543-548.Palumbo, T., Faucz, F.R., Azevedo, M., et al. (2013) Functional Screen Analysis Reveals miR-26b and miR-128 as Central Regulators of Pituitary Somatomammotrophic Tumor Growth through Activation of PTEN-AKT Pathway. Oncogene, 32, 1651-6459. <br>https://doi.org/10.1038/onc.2012.190Tsuchiya, S., Fujiwara, T., Sato, F., Shimada, Y., Tanaka, E., Sakai, Y., Shimizu, K. and Tsujimoto, G. (2011) MicroRNA-210 Regulates Cancer Cell Proliferation through Targeting Fibroblast Growth Factor Receptor-Like 1 (FGFRL1). Journal of Biological Chemistry, 286, 420-428. <br>https://doi.org/10.1074/jbc.M110.170852Amaral, F.C., Torres, N., Saggioro, F., et al. (2009) MicroRNAs Differentially Expressed in ACTH-Secreting Pituitary Tumors. The Journal of Clinical Endocrinology & Metabolism, 94, 320-323. <br>https://doi.org/10.1210/jc.2008-1451Li, S., Yang, J., Wang, J., et al. (2018) Down-Regulation of miR-210-3p Encourages Chemotherapy Resistance of Renal Cell Carcinoma via Modulating ABCC1. Cell & Bioscience, 8, 9. <br>https://doi.org/10.1186/s13578-018-0209-3Morita, K., Takano, K., Yasufuku-Takano, J., et al. (2008) Expression of Pituitary Tumour-Derived, N-Terminally Truncated Isoform of Fibroblast Growth Factor Receptor 4 (ptd-FGFR4) Correlates with Tumour Invasiveness But Not with G-Protein Alpha Subunit (Gsp) Mutation in Human GH-Secreting Pituitary Adenomas. Clinical Endocrinology, 68, 435-441.